Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Olaparib Monotherapy in Advanced Oesophagogastric Cancer
2018-000454-22Phase 2Unknown
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olaparib in esophageal adenocarcinoma (EAC), gastroesophageal junction adenocarcinoma and gastric adenocarcinoma, sponsored by Royal Marsden NHS Foundation Trust. Primary endpoint: Disease control rate at 8 weeks. Status: unknown.
02
Drugs
olaparib
03
Conditions
esophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinomagastric adenocarcinoma
Beyond the preview
Go deeper on 2018-000454-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000454-22.